Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
about
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.Antiretroviral therapy in HIV-infected adolescents: clinical and pharmacologic challenges.Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure.
P2860
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
@en
type
label
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
@en
prefLabel
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
@en
P2093
P2860
P1433
P1476
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents
@en
P2093
Andrew Wiznia
Jacobo Abadi
Rolando M Viani
P2860
P2888
P304
P356
10.1007/S40265-015-0446-2
P577
2015-09-01T00:00:00Z
P5875
P6179
1002191671